DeepMed Research

University Of Maryland, Baltimore

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1807-01-01

Employees: 7.3K

Market Cap: -

Website: http://www.umaryland.edu

Clinical Trials

Improving Glycemic Control in DM2 Patients in the Ambulatory Setting

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Other: Point of Care Glucose Group
Device: Smart insulin pens and CGM

First Posted Date: 2021-03-16

Last Posted Date: 2024-07-10

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 30

Registration Number: NCT04800471

Locations: 🇺🇸
Baltimore VA Medical Center, Baltimore, Maryland, United States

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)

First Posted Date: 2021-03-08

Last Posted Date: 2025-02-27

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 10

Registration Number: NCT04786457

Locations: 🇺🇸
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Phase 1

Recruiting

Conditions: Glioma

Interventions: Drug: Hyperpolarized 13C-Pyruvate

First Posted Date: 2021-02-26

Last Posted Date: 2024-07-19

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 5

Registration Number: NCT04772456

Locations: 🇺🇸
Rosy Njonkou Tchoquessi, Baltimore, Maryland, United States

Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure

Phase 4

Completed

Conditions: Vivax Malaria

Interventions: Drug: Primaquine
Drug: Artesunate

First Posted Date: 2021-01-12

Last Posted Date: 2025-03-28

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 160

Registration Number: NCT04706130

Locations: 🇰🇭
Institut Pasteur du Cambodge, Phnom Penh, Cambodia

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Hyperpolarized 13C-Pyruvate

First Posted Date: 2021-01-07

Last Posted Date: 2024-07-19

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 20

Registration Number: NCT04698564

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

Not Applicable

Recruiting

Conditions: Glioblastoma
Brain Tumor
Glioma

Interventions: Procedure: LITT
Radiation: Hypofractionated Radiation Therapy

First Posted Date: 2021-01-07

Last Posted Date: 2025-03-21

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 32

Registration Number: NCT04699773

Locations: 🇺🇸
Maryland Proton Treatment Center, Baltimore, Maryland, United States
🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
UCH Kaufman Cancer Center, Bel Air, Maryland, United States

and more 2 locations

Teletherapy for Upper Extremity Fracture Rehabilitation (TELE-REHAB Study)

Not Applicable

Withdrawn

Conditions: Upper Limb Surgery
Occupational Therapy

Interventions: Other: occupational therapy

First Posted Date: 2020-12-31

Last Posted Date: 2023-11-30

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT04691739

Locations: 🇺🇸
U of Maryland, Baltimore, Maryland, United States

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Phase 1

Active, not recruiting

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Drug: Venetoclax and pegcrisantaspase

First Posted Date: 2020-12-14

Last Posted Date: 2024-10-29

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 27

Registration Number: NCT04666649

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

Phase 4

Completed

Conditions: Polysorbate 80
Bile Salt Export Pump (BSEP) Transporter

Interventions: Drug: pravastatin and chenodeoxycholic acid, after metformin and placebo
Drug: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo

First Posted Date: 2020-11-23

Last Posted Date: 2024-07-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 18

Registration Number: NCT04640571

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

Shigella CVD 31000: Study of Responses with Shigella-ETEC Vaccine Strain CVD 1208S-122

Phase 1

Completed

Conditions: Shigella Infection
Enterotoxigenic Escherichia Coli Infection

Interventions: Biological: strain CVD 1208S-122
Other: Placebo

First Posted Date: 2020-11-18

Last Posted Date: 2025-01-24

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 53

Registration Number: NCT04634513

Locations: 🇺🇸
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy